Golimumab for Rheumatoid Arthritis

@inproceedings{Pelechas2019GolimumabFR,
  title={Golimumab for Rheumatoid Arthritis},
  author={Eleftherios Pelechas and Paraskevi V Voulgari and Alexandros A Drosos},
  booktitle={Journal of clinical medicine},
  year={2019}
}
Since the advent of infliximab for the treatment of rheumatoid arthritis (RA), new genetically-engineered molecules have appeared. This review aims to present the current data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity are all being investigated, not only through phase III trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-MORE, GO-FURTHER, GO-NICE), but also through studies of real-world data. It seems that GLM in the subcutaneous form is an… CONTINUE READING
2
Twitter Mentions

Similar Papers

Tables and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Etanercept biosimilar SB-4.

  • Expert opinion on biological therapy
  • 2019
VIEW 1 EXCERPT

Golimumab retention rate in patients with rheumatoid arthritis. Predictors of long-term retention [abstract

B. Serrano, C. M. Gonzalez, +7 authors I Monteagudo
  • Arthritis Rheumatol. 2017,
  • 2018
VIEW 1 EXCERPT